Gain Therapeutics (GANX) Competitors $2.16 +0.12 (+5.61%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. AARD, PRME, SOPH, NGNE, CRGX, AMRN, ANNX, OCGN, ITOS, and YMABShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Aardvark Therapeutics (AARD), Prime Medicine (PRME), SOPHiA GENETICS (SOPH), Neurogene (NGNE), CARGO Therapeutics (CRGX), Amarin (AMRN), Annexon (ANNX), Ocugen (OCGN), iTeos Therapeutics (ITOS), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Aardvark Therapeutics Prime Medicine SOPHiA GENETICS Neurogene CARGO Therapeutics Amarin Annexon Ocugen iTeos Therapeutics Y-mAbs Therapeutics Aardvark Therapeutics (NASDAQ:AARD) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation. Do analysts prefer AARD or GANX? Aardvark Therapeutics currently has a consensus price target of $31.50, suggesting a potential upside of 193.84%. Gain Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 278.75%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media refer more to AARD or GANX? In the previous week, Gain Therapeutics had 6 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 8 mentions for Gain Therapeutics and 2 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.94 beat Gain Therapeutics' score of 0.69 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in AARD or GANX? Gain Therapeutics received 31 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Aardvark Therapeutics an outperform vote while only 73.08% of users gave Gain Therapeutics an outperform vote. CompanyUnderperformOutperformAardvark TherapeuticsOutperform Votes7100.00% Underperform VotesNo VotesGain TherapeuticsOutperform Votes3873.08% Underperform Votes1426.92% Do institutionals and insiders believe in AARD or GANX? 12.0% of Gain Therapeutics shares are held by institutional investors. 11.7% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation & earnings, AARD or GANX? Aardvark Therapeutics has higher earnings, but lower revenue than Gain Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/AN/AN/AN/AGain Therapeutics$50K1,244.70-$22.27M-$0.92-2.35 Is AARD or GANX more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Gain Therapeutics N/A -203.91%-128.05% SummaryGain Therapeutics beats Aardvark Therapeutics on 9 of the 13 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.67M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-1.987.3822.6318.55Price / Sales1,244.70241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book2.236.476.704.25Net Income-$22.27M$143.68M$3.23B$248.27M7 Day Performance15.16%1.85%1.36%1.28%1 Month Performance19.61%6.73%3.85%3.75%1 Year Performance-27.10%-2.72%15.87%5.31% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.8161 of 5 stars$2.17+5.6%$8.20+278.8%-30.0%$62.67M$50,000.00-1.9820News CoverageAARDAardvark TherapeuticsN/A$10.12+27.6%$31.50+211.3%N/A$219.56MN/A0.0018PRMEPrime Medicine2.4184 of 5 stars$1.66-1.8%$13.38+705.7%-64.8%$217.73M$2.98M-0.81234SOPHSOPHiA GENETICS2.36 of 5 stars$3.26+3.2%$6.80+108.6%-40.2%$217.40M$65.17M-2.99520Upcoming EarningsNews CoverageHigh Trading VolumeNGNENeurogene2.0361 of 5 stars$14.50-5.9%$47.20+225.5%-56.5%$216.49M$925,000.00-3.4090Positive NewsCRGXCARGO Therapeutics2.0858 of 5 stars$4.63+2.7%$15.00+224.0%-76.1%$213.22MN/A-1.09116News CoveragePositive NewsAMRNAmarin0.5518 of 5 stars$10.32-1.1%$7.00-32.2%-41.6%$211.91M$228.61M-114.67360Upcoming EarningsAnalyst RevisionPositive NewsANNXAnnexon2.0316 of 5 stars$1.89+0.5%$18.67+887.7%-59.1%$207.35MN/A-1.8060Positive NewsOCGNOcugen1.0302 of 5 stars$0.71-1.3%$6.33+792.0%-43.4%$207.33M$4.06M-3.9480News CoverageITOSiTeos Therapeutics2.0936 of 5 stars$7.07-3.8%$25.75+264.2%-32.5%$205.87M$35M-2.2490Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageYMABY-mAbs Therapeutics3.8197 of 5 stars$4.23+3.2%$17.40+311.3%-72.1%$205.29M$87.69M-7.83150Upcoming EarningsShort Interest ↓News Coverage Related Companies and Tools Related Companies Aardvark Therapeutics Alternatives Prime Medicine Alternatives SOPHiA GENETICS Alternatives Neurogene Alternatives CARGO Therapeutics Alternatives Amarin Alternatives Annexon Alternatives Ocugen Alternatives iTeos Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GANX Stock Free GANX Stock Alerts